AC
SPRY icon

AXQ Capital’s ARS Pharmaceuticals SPRY Stock Holding History

AXQ Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
26,741
-37,563
-58% -$323K 0.02% 708
2026
Q1 		$516K Buy
+64,304
New +$616K 0.07% 406

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AXQ Capital's SPRY Position: Q2 2026 in Review

AXQ Capital reduced its ARS Pharmaceuticals (SPRY) stake by 58% in Q2 2026, selling an estimated $323K and leaving 26,741 shares worth $214K. The position accounts for 0.02% of the portfolio, ranked #708.

AXQ Capital first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. The position peaked at $516K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • AXQ Capital held 26,741 shares of ARS Pharmaceuticals worth $214K as of Q2 2026.
  • AXQ Capital sold 37,563 ARS Pharmaceuticals shares in Q2 2026, an estimated $323K.
  • ARS Pharmaceuticals made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #708 holding.
  • AXQ Capital first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • AXQ Capital's ARS Pharmaceuticals position peaked at $516K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.